Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group

Epilepsia
E FaughtW Rosenfeld

Abstract

Valproate (VPA) triples the half-life of lamotrigine (LTG), and combined use may be difficult. The adverse effect (AE) profile of this combination needs clarification. We prospectively recorded our experience in adding LTG to VPA-containing regimens in 108 patients. Data collected included medications, seizure types and syndromes, and AEs. Patients were followed up to 27 months, until a stable dose was reached, or until LTG was discontinued. Patient management was not altered by this study. There were 60 patients with partial-onset seizures, 30 with generalized onset, and 12 with the Lennox-Gastaut syndrome. In 37, LTG was added to VPA monotherapy, and in 71, to VPA and other drugs. The median starting dose of LTG in our adult patients was 20.8 mg/day. LTG was added successfully in 86 (80%) patients. It was discontinued in 22 (20%): seven because of rash, seven for other AEs, and nine for other reasons. Rash occurred in 14 (13%) but caused discontinuation of LTG in only seven. We found a rash rate of 14.2% and a discontinuation rate because of rash of 8.7% among 310 patients in whom LTG was added to drug regimens not including VPA. Other AEs included fatigue (12%), gastrointestinal (GI) symptoms (9%), dizziness, headache, and i...Continue Reading

References

Mar 1, 1992·Seizure : the Journal of the British Epilepsy Association·T Betts
Jun 6, 1992·Lancet·M J Brodie
Jan 1, 1991·Epilepsia·T BettsA W Yuen
Jun 1, 1984·Journal of Neurology, Neurosurgery, and Psychiatry·D ChadwickD M Turnbull
Jan 1, 1994·Epilepsia·A Richens
Jan 1, 1994·Epilepsia·M A Granner, S I Lee
Mar 1, 1994·Epilepsia·E SchlumbergerO Dulac
Dec 1, 1995·The Journal of Pediatrics·F M BesagG Hosking
Jan 1, 1996·Neurology·J DooleyE Smith

❮ Previous
Next ❯

Citations

Nov 26, 2008·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Adeline Ngo Su-YinKent R Olson
Jan 3, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Steven C Schachter
Mar 29, 2000·Pediatric Neurology·R StraussbergJ Amir
Apr 5, 2008·The Nurse Practitioner·Christina K RobertsNitin C Patel
Sep 2, 2011·The Neurologist·Nicholas Tiberio EconomouAndreas Kyrozis
Feb 28, 2006·Epilepsia·Lawrence J HirschStanley R Resor
Nov 23, 2006·Epilepsia·Bernhard J Steinhoff
Jan 1, 2011·BMJ Case Reports·Fayaz A SofiG N Dhobi
Jan 7, 2006·CNS Drugs·Daniel LinLakshmi N Yatham
Dec 13, 2002·American Journal of Clinical Dermatology·Julia K Warnock, David W Morris
Jun 8, 2001·Paediatric Drugs·C P Panayiotopoulos
Nov 19, 2003·Psychopharmacology Bulletin·Michael J Owens, Charles B Nemeroff
Jan 24, 2002·Therapeutic Drug Monitoring·Houda HachadRene H Levy
Sep 15, 2000·Current Opinion in Neurology·E Ben-Menachem
Oct 31, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·F C FervenzaD J Lager
Jun 8, 2013·Pharmacological Reports : PR·Barbara BłaszczykWładysław Lasoń
May 15, 2013·Pediatric Neurology·Sigride Thome-Souza, Kette D Valente
Jan 31, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Chuan-Chia ChangHsin-An Chang
Oct 18, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Chuan-Chia ChangSan-Yuan Huang
Jul 15, 2015·Clinical and Molecular Hepatology·Sung Gyu ImMi Jung Oh
May 3, 2015·Pharmacological Reports : PR·Barbara BłaszczykStanisław Jerzy Czuczwar
Jun 14, 2000·Seizure : the Journal of the British Epilepsy Association·B E GidalP Rutecki
Nov 20, 2012·Dermatologic Clinics·Mansi PatelRodney Sinclair
Sep 25, 2008·Arquivos de neuro-psiquiatria·Karen P GrisottoLúcia H C Santos
Mar 2, 2005·Acta Neurologica Scandinavica·S P-Codrea TigaranM Dam
Apr 21, 2010·Expert Opinion on Pharmacotherapy·Benjamin Cretin, Edouard Hirsch
Dec 21, 2012·Journal of Investigative and Clinical Dentistry·Sreekanth K MallineniNigel M King
Apr 30, 2002·The Annals of Pharmacotherapy·Stephen C Hurley
May 18, 2021·Expert Review of Neurotherapeutics·Michele AscoliEdoardo Ferlazzo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.